Evolus EOLS Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Evolus in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The official record: Evolus’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Evolus's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Evolus's business segments — R&D?
- Evolus (EOLS) reported business segments — R&D of $2.24M in Q1 2026.
- How has Evolus's business segments — R&D changed year-over-year?
- Evolus's business segments — R&D increased by 1.3% year-over-year, from $2.21M to $2.24M.
- What is the long-term trend for Evolus's business segments — R&D?
- Over 3 years (2022 to 2025), Evolus's business segments — R&D has grown at a 28.9% compound annual growth rate (CAGR), from $4.47M to $9.58M.
- What does business segments — R&D mean?
- Captures the expenses incurred by the segment for scientific research, clinical trials, and the development of new aesthetic product formulations. It reflects the company's commitment to innovation and long-term pipeline growth within the self-pay aesthetic market.